[In response to a question, he said it was impossible to give] any reliable estimate ... All those estimates are just speculation.

Our goal is not to be just one of the largest pharmaceutical companies, but also to be one of the fastest growing,

Remarkably, for the first 18 months there was no difference so it was consistent with all our other data and at 18 months the risk started to build and we saw the data, we withdrew the drug,

subject to market conditions.

The fourth quarter profit was below estimates, my estimate was €590m or 44 cents per share.

They may be worn out, over-used, mishandled, abused. It is a question of how reliable is the source you got it from. Unfortunately, that is not always a very safe bet.